Zoetis Reports $9.47B Revenue for 2025, Provides 2026 Guidance
Zoetis Inc. (NYSE: ZTS) reported full year 2025 financial results on February 12, 2026, delivering earnings per share of $6.02 on revenue of $9.47 billion, as the animal health company continues to capitalize on growing demand for pet care and livestock products.
Key Numbers
The animal pharmaceutical giant posted full year 2025 revenue of $9.47 billion, representing solid growth in both its companion animal and livestock segments. Earnings per share reached $6.02 for the year, with net income totaling $2.67 billion.
Fourth quarter performance capped off the strong year, with implied Q4 revenue of approximately $2.39 billion based on the company's reported nine-month and full-year figures. This represents a sequential improvement from Q3 2025's $2.40 billion in quarterly revenue.
The company's operational performance throughout 2025 demonstrated consistent execution, with third quarter revenue of $2.40 billion and second quarter revenue reaching a notably higher $4.68 billion, suggesting potential seasonal patterns in the business or the impact of specific product launches during the middle of the year.
Net income margins remained healthy throughout the year, with the company converting $2.67 billion of its $9.47 billion in revenue to bottom-line profits, representing a net margin of approximately 28%. This profitability underscores Zoetis's pricing power in the animal health market and its ability to manage costs effectively despite inflationary pressures.
What Management Said
While the detailed management commentary from the earnings press release was not immediately available in the 8-K filing, the company indicated it has provided guidance for full year 2026 in its press release announcement. The filing was signed by Executive Vice President and Chief Financial Officer Wetteny Joseph, signaling confidence in the reported results.
The timing of the earnings release, coming in mid-February for the fourth quarter ending in December, follows Zoetis's typical reporting calendar. The company's decision to provide 2026 guidance alongside the earnings results suggests management confidence in the underlying business momentum and visibility into demand trends for both companion animal and livestock products.
What to Watch
Investors should focus on several key factors as Zoetis moves into 2026. The company's ability to maintain its strong profitability margins will be crucial, particularly as it faces potential headwinds from generic competition for some of its key products and ongoing cost pressures in the global supply chain.
The companion animal segment remains a critical growth driver for Zoetis, benefiting from the humanization of pets trend and increased spending on pet healthcare. The livestock segment, while potentially more cyclical, provides important diversification and benefits from global protein demand growth.
The 2026 guidance provided by management will offer important insights into expected growth rates and margin expectations for the year ahead. Key areas to monitor include the company's pipeline of new products, particularly in areas like monoclonal antibodies for pets and alternatives to antibiotics in livestock.
Additionally, Zoetis's international expansion efforts, particularly in emerging markets where pet ownership is rising and livestock production is modernizing, represent significant long-term growth opportunities. The company's ability to execute on these opportunities while maintaining operational excellence will be critical for sustaining its premium valuation in the animal health sector.
The sequential revenue patterns observed in 2025, with particularly strong Q2 performance, suggest investors should pay attention to potential seasonality or product launch timing that could impact quarterly comparisons going forward.
*Source: SEC Form 8-K filed February 12, 2026*
*StockCliff Research*